iX Biopharma's drug for treating male erectile dysfunction has just been approved for sale in Singapore.

Silcap10.20Silcap capsules are small and taken orally while Wafesil wafers (not available in S'pore) are placed under the tongue where the drug is absorbed into the blood vessels.The product, Silcap®, has obtained approval and registration by the Health Sciences Authority, says Singapore-listed specialty pharmaceutical company iX Biopharma.

There is already a variety of generic treatment options but Silcap® is designed as a novel small capsule, unlike existing alternatives which are typically delivered in tablet form.


Silcap® is the first capsule sildenafil product to obtain marketing approval in Singapore.

Silcap® is iX Biopharma’s second drug for the treatment of male erectile dysfunction after Wafesil®.

The latter is a novel dose form of sildenafil delivered using iX Biopharma’s proprietary WaferiX® drug delivery technology, a sublingual wafer that delivers drug actives safely, conveniently and rapidly into the blood stream.

iX Biopharma also supplies Silcap® and Wafesil® in Australia since obtaining approval and registration in 2018 from the Therapeutic Goods Administration (TGA), the regulatory authority in Australia.

EvanTan7.19Ms Eva Tan, Director, Corporate and Commercial Strategy of iX Biopharma, said: “We are delighted with the approval and registration of Silcap® in Singapore. Apart from offering a unique value proposition when compared to existing sildenafil products in the market, Silcap® ’s approval continues to reaffirm our ability to bring products successfully from clinical development to registration and launch.”


Silcap® is available in dosage strengths of 25 mg and 50 mg in pack sizes of 4, 8 and 12 capsules.

iX Biopharma will be preparing for marketing launch of Silcap® in Singapore.

As sildenafil drugs are classed as prescription medication in Singapore, Silcap® will be supplied via licensed medical practitioners.

iX Biopharma cited a study that said erectile dysfunction is a common condition affecting one in five men over the age of 40 years 1.

In a population-based survey conducted in Singapore on men greater than 30 years old, a prevalence rate of male erectile dysfunction of 51.3% was observed, whereas another study on the ageing population in the country reported a prevalence rate of 73.0% 2.

1 “Assessment and Management of Infertility at Primary Healthcare Level”, Academy of Medicine Singapore, 2013

2 “Male sexual dysfunction in Asia”, Asian Journal of Andrology, 2011


Erectile dysfunction is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance, and these problems may be related to a wide variety of factors.

Erectile dysfunction is common among older men and is often associated with chronic illnesses including atherosclerosis, diabetes and depression. It is also associated with certain prescription medications and alcohol consumption.


Share Prices

Counter NameLastChange
AEM Holdings3.560-0.070
Avarga0.315-0.010
Avi-Tech Electronics0.400-
BH Global0.320-
China Sunsine0.535-
Food Empire0.8850.005
Fortress Minerals0.5700.025
Golden Energy0.153-0.004
GSS Energy0.060-
InnoTek0.9500.005
ISDN Holdings0.6400.005
ISOTeam0.135-
IX Biopharma0.240-0.005
KSH Holdings0.365-
Leader Env0.130-0.010
Medtecs Intl1.040-0.030
Moya Asia0.068-
Nordic Group0.245-0.010
Oxley Holdings0.245-
Procurri0.335-
REX International0.1800.001
Riverstone1.340-0.030
Roxy-Pacific0.355-0.005
Southern Alliance Mining0.9650.005
Sri Trang Agro2.040-0.050
Straco Corp.0.555-
Sunpower Group0.8950.020
The Trendlines0.104-0.001
UG Healthcare0.660-0.040
Uni-Asia Group0.665-
Wilmar Intl4.970-0.010
Yangzijiang Shipbldg1.5200.060
Yinda Infocomm0.1490.001

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 846 guests and no members online